Oral Anticoagulation Therapy in Atrial Fibrillation Patients with Advanced Chronic Kidney Disease: CODE-AF Registry.

Yonsei Med J · 2023 · PMC9826956 · PMID 36579375

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

28 In this trial, composite myocardial infarction, stroke, and cardiovascular death were significantly reduced in the rivaroxaban 2.5-mg twice daily plus aspirin group, and there was a nonsignificant trend toward reduced risk in the rivaroxaban 5-mg twice daily group compared to the aspirin only group.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.